A novel human gene, LAF-4, was isolated from a subtracted cDNA library that showed strong sequence similarity t o AF-4, a gene that is translocated in t(4;11)(q21;q23) acute lymphoblastic leukemias (ALLs). In t(4;ll) ALL, the AF-4 gene at 4q21 is translocated into the MLL locus at 11q23, resulting in the expression of an MLL/AF4 fusion protein that is the presumptive oncoprotein. AF-4 and LAF-4 are homologous throughout their coding regions, yet neither protein is related t o previously cloned genes. Human LAF-4 readily hybridized with genes in mouse and chicken, thus showing that this gene family has been highly conserved during vertebrate evolution. In mouse tissues, LAF-4 mRNA was found t o be present at highest levels in lymphoid tissues, present at lower levels in brain and lung, and absent from other tissues. In human and mouse lymphoid cell lines, HE RECURRENT t(4; 1 l)(q21;q23) in acute lymphoblastic leukemia (ALL) has profound clinical importance because it is present in approximately 50% of the ALL cases in children under 1 year of age.' Furthermore, this translocation defines a subgroup of pediatric ALL that has an especially poor prognosis.' The t(4; 11) belongs to a class of translocations in acute leukemias that involve a human homologue of the Drosophila trithorax gene, the MLL gene (also termed ALL-l, HRX, HTRX).'.' The MLL gene is translocated to more than 10 different chromosomal loci, resulting in acute myeloid, acute monocytic, acute myelomonocytic, or acute lymphocytic leukemias.' Each translocation generates an in-frame fusion protein between the amino terminus of MLL and the carboxy terminus of the translocation partner. The reciprocal translocation product, encoding the carboxy terminus of MLL, is lost in 25% of cases and, thus, is not likely to be central to the transformation process.' Interestingly, the lineage of the acute leukemia that results from the translocation correlates well with the MLL fusion partner.' For example, the t(4; 1 l ) fuses MLL to the AF-4',' (also termed FELR) gene and is found almost exclusively in a subtype of ALL that has been termed "biphenotypic" because of the coexpression of lymphoid and myeloid cell surface markers. By contrast, the t(9; 11) fuses MLL to the AF-9 gene7 and is always found in acute myeloid leukemias (AMLs). Because the region of MLL included in each fusion protein is virtually identical, the fusion partner appears to influence the lineage restriction of the leukemia.
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The various fusion partners of MLL are all novel proteins LAF-4 expression was highest in pre-B cells, intermediate in mature B cells, and absent in plasma cells, thus pointing to a potential regulatory role for LAF-4 in lymphoid development. Antibodies t o LAF-4 showed it to be a nuclear protein that showed an uneven, granular immunofluorescence pattern. In vitro-translated LAF-4 was able t o bind strongly t o doublestranded DNA cellulose. Furthermore, both LAF-4 and AF-4 had domains that activated transcription strongly when fused to the GAL4 DNA-binding domain. Interestingly, the AF-4 transactivation domain is retained in the MLL/AF4 fusion protein; thus, it may contribute to the transforming potential of the oncoprotein. Therefore, the cloning of LAF-4 has defined a new family of potential regulatory proteins that may function in lymphoid development and oncogenesis. 0 1996 by The American Society of Hematology.
that generally do not belong to known families. Nevertheless, several of the proteins contain putative nuclear localization sequences (NLSs) and, thus, may be nuclear factors. Indeed, the ENL protein that is fused to MLL in t( 11 ; 19) leukemias has recently been localized to the nucleus. ' The AF-4 protein shows no strong similarity to previously characterized proteins, but it does contain a potential NLS.7.4,7.x Here, we present the cloning and characterization of LAF-4, a homologue of AF-4, that is preferentially expressed in lymphocytes. This study shows that LAF-4 and AF-4 are founding members of a new family of nuclear factors with the potential to regulate transcription.
MATERIALS AND METHODS
DNA methods. Routine molecular biological methods were performed essentially as described.'" Standard conditions for polymerase chain reaction (PCR) amplification were, unless otherwise stated, 30 seconds at 94"C, 30 seconds at 55T, and I minute at 72°C for 30 cycles with the indicated primers and either Taq DNA polymerase (Boehringer Mannheim, Indianapolis, IN) or pfu DNA polymerase (Stratagene, La Jolla, CA) under the conditions recommended by the manufacturer. All PCR products were confirmed by DNA sequencing.
Cloning LAF-4 and AF-4 cDNAs. The initial probe for LAF-4 was derived from a cDNA (AD1437; see Fig 1) present in a subtracted cDNA library enriched in genes expressed in the Raji Burkitt's lymphoma cell line and not in the K562 erythroleukemia cell line." By automated DNA sequencing of 1,290 subtracted cDNA clones and homology searching against the Genbank database (National Center for Biotechnology Information, Bethesda, MD), we identified those genes that were novel. Examination of the predicted coding regions of these cDNAs showed a subset of cDNAs that could encode a potential nuclear localization signal. One of these cDNAs additionally showed homology to AF-4 and was chosen for further analysis. This subtracted cDNA was used to identify the complete coding region of LAF-4 using a cloning strategy shown in Fig 1. The AD1437-subtracted cDNA clone was used to screen an oligo-dT-primed cDNA library prepared in the Lambda Zap 11 cloning vector (Stratagene) from the Raji Burkitt's lymphoma cell line resulting in the E4 I cDNA clone (Fig 1) that encoded the aminoterminal 307 amino acids of LAF-4. A PCR cloning method was then used to "walk" 3' of this initial clone. Specifically, we used an oligonucleotide primer 5'-CCCGGAATTCGAGAGTAGATC-TGGAGAAACCAAC-3' from the 3' end of the E41 clone and an oligonucleotide (T3 or T7 primer) derived from the sequence of the Lambda Zap I1 cloning vector to amplify by pfu-PCR the cDNA sequence encoding amino acids 292 to 475 using, as a template, a randomly primed cDNA library (in Lambda Zap 11) derived from chronic lymphocytic leukemia (CLL) cells (clone E3938; see Fig   1) . Two further long cDNA clones (E5 and E19: see Fig 1) were then obtained by screening the Raji cDNA library using this PCRgenerated fragment as a probe. Both long clones contained the remainder of the coding region of LAF-4. The E19 clone additionally contained the entire 3' untranslated region (=4.5 kb) including the polyadenylation signal. Full-length LAF-4 cDNA was assembled into Xba VAsp718 sites in pBlueScript (Stratagene) using natural restriction fragments generated from the E41 (Xba I-Bgl I1 [amino acid 2951) and E5 (Pst I [amino acid 4021-Asp718) cDNA clones, with the exception of the region encoding amino acids 295 (Bgl 11) to 402 (Psr I) that was derived from the CLL library by PCR amplification using pfu DNA polymerase (Stratagene).
A partial cDNA for mouse LAF-4 (mElOl, Fig 1) was obtained by screening an oligo-dT-primed A gtl 1 cDNA library derived from the 22D6 mouse pre-B cell line (a kind gift of Dr A. Winoto, University of California at Berkeley, CA) with "P-labeled human LAF-4 cDNA probes corresponding to amino acids 1-294 and 368-1188. Probe 1-294 was prepared from an X h YBgl I1 0.84-kb fragment from E41, and probe 368-1 188 was an EcoRI 2.5-kb fragment from E5. Clones that showed positive signals from both probes were picked and analyzed further. One of the double-positive clones, mElOl, contains 39 bp of 5' untranslated region and the first 2004 bp of the LAF-4 coding region. Both human and mouse LAF-4 cDNA sequences have been submitted to the Genbank database and have been given accession no. U34360 and U34361, respectively.
A cDNA fragment corresponding to the amino-terminal 650 amino acids of AF-4 type A cDNA8 was amplified by a reverse transcription-PCR (RT-PCR) protocol using poly-A-selected RNA from the Raji cell line. First-strand cDNA was synthesized by SuperScript reverse transcriptase (GIBCO-BRL, Gaithersburg, MD) using the RT primer 5'-TCCTITCGTCTTCACCTI'GGGCTI"3'. The initial PCR reactions were performed by using Taq polymerase (Boehringer Mannheim) with the RT primer and the primer 5"CTAGCCACT-TTGCATTGACTGGAA-3'. The PCR protocol was 30 cycles of 30 seconds at 94'32, 30 seconds at 60°C. and 1 minute at 72°C. The second PCR was performed under the same conditions with two nested primers S'-GATCTCTAGAACAATGGCATT-TACAGAAAGAGTCAAC-3' and 5'-GGCTTGTC'ITTGGAAGT-CTGGTCT-3'. The final PCR product was cloned into the pCRII vector using a TA cloning kit (Invitrogen, San Diego, CA). This PCR-generated fragment was used to screen the CLL random-primed cDNA library to obtain a 1.4-kb partial AF-4 cDNA (clone FELN-1B) corresponding to AF-4 amino acids 46 to 509 (Fig 2A) .
Northern blot analysis. Total cellular or tissue RNA (mouse strain C57BU6) was prepared using the guanidinium isothiocyanatel phenol chloroform extraction method (RNA isolation kit: Stratagene) according to the manufacturer's protocol. Polyadenylated mRNA was purified using oligo-dT cellulose chromatography (Collaborative Biomedicals, Bedford, MA). A total of 2 to 3 pg of poly-A-containing mRNA (Fig 3A) or 20 pg of total RNA (used in the mouse cell line Northern summarized in Table 1 ) was used for Northern blot analysis as described." The human Northern blot was hybridized with a 3zP-labeled human LAF-4 cDNA probe corresponding to amino acids 1-296 that is derived from the E41 LAF-4 cDNA clone using pfu PCR with primers 5'-GCCGGAATTCCCACCATGGAC-AGCTTCGACTI'-3' and 5'-GCWX3AATTCCAGATCTACTC-TCCTCCCCCTG-3'. The mouse Northern blot was hybridized with a 32P-labeled probe prepared using the 2.04-kb insert of the m E l O l partial mouse LAF-4 cDNA clone (Fig 1) . The Northern blots were reprobed with a GAPDH probe excised from a 1.2-kb Pst I fragment of a rat GAPDH cDNA clone."
RNase protection assay. Because the 8.5-kb human LAF-4 mRNA species did not always transfer completely during Northern blot analysis, we designed an RNase protection assay for huamn LAF-4 mRNA to provide a quantitative measure of human LAF-4 mRNA abundance. The LAF-4 cDNA sequence corresponding to amino acids 19-92 was amplified by pfu-PCR from E41 and cloned into the TA vector (pCRII; Invitrogen) using primers S'GTCTAT-GAACCAGATAG-3' and 5'-GAGATGACTCTGAlTGG-3'. An antisense, 3zP-uridine-5'-triphosphate-labeled, riboprobe was generated from this plasmid using SP6 RNA polymerase (Promega, Madison, WI), following the manufacturer's protocol, after linearization with Xba I. A control actin riboprobe (Ambion, Austin, TX) was similarly generated using SP6 RNA polymerase. The RNase protection assay was performed using a kit according to the manufacturer's protocol (Promega). To compensate for the greater abundance of actin mRNA than LAF-4 mRNA, the in vitro-transcription reaction conditions were adjusted so that the specific activity of the LAF-4 riboprobe was 10-fold higher than that of the actin riboprobe. Gelpurified riboprobes (lo6 cpm of LAF-4 probe and IO5 cpm of actin probe) were annealed with 30 pg of total RNA at 50°C for 16 hours. The protected bands were 220 bp and 127 bp in length for LAF-4 and actin, respectively.
Preparation of LAF-I antiserum. The cDNA sequence corresponding to the amino acids 17-307 of human LAF-4 was amplified by Taq-PCR using primers 5'-CCCGGAATI'CTGTGTGTCT-GAACCAGATAGA-3' and 5'-GCCGGAAlTCCGGAlTA'ITTC-ITCAACACAGCTG-3' and was cloned into the EcoRI site of the bacterial expression vector, pGEX-2TK. 13 The expression of the glutathione S-transferase (GST)LAF-4 fusion protein was induced by growth of bacteria at 30°C for 1.5 hours in 0.1 mmoVL isopropyl-P-D-thiogalactoside (IPTG). Bacteria were pelleted by centrifugation and were resuspended in cold phosphate-buffered saline (PBS) containing 0.5 mmoW phenylmethylsulfonyl fluoride (PMSF) and 1% Triton X-100 (Pharmacia, Piscataway, NJ). Bacteria were lysed by 8 to 12 cycles of a 15-second pulse followed by a 15-second interval at 4°C using a sonicator (Heat Systems, Farmingdale, NY). Bacterial debris was removed by centrifugation, and the GSTLAF-4 fusion protein was affinity-purified by adding glutathione-coupled Sepharose 4B (Pharmacia) to the supernatant. GSTLAF-4 fusion protein was then eluted with a buffer containing 100 mmoVL Tris-HC1, 120 mmoVL NaCI, and 20 mmoVL reduced glutathione (Sigma, St Louis, MO). The full-length, 58-kD GSTLAF-4 fusion protein was purified by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE), concentrated using a Centricon 30 filter (Amicon) and dialyzed against PBS. A total of 500 pg of GSTLAF-4 was emulsified with complete Freund's adjuvant and injected into rabbits as a primary immunization. A total of 200 pg of GSTLAF- 4 was emulsified in incomplete Freund's adjuvant and used for four subsequent booster immunizations administered at 2-week intervals. Two rabbits were used for this protocol, although only one rabbit produced high-titered antiserum. The progress of the immunization procedure was monitored by Western blot analysis using lysates from cell lines that express LAF-4. Antibodies to GST were removed from the crude antiserum by chromatography through a GST-conjugated Affigel 10 column (Bio-Rad, Heredes, CA). Anti-LAF-4 antibody was then affinity-purified by chromatography on a GSTI LAF-4-conjugated Affigel 10 column (Bio-Rad). Antibody was eluted with 0. I molL glycine (pH 2.5) and neutralized immediately with 1 molL Tris-HC1 (pH 8.1).
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Western blot analysis. Whole cell lysates were prepared at 4°C in SDS lysis buffer (0.2% SDS/50 mmolL Tris-Cl, [pH 8.0]/150 mmoUL NaCI, containing 10 mg/mL aprotinin and 1 mmoUL PMSF) using 5 X lo6 cells/mL of the lysis buffer. Genomic DNA in the lysates was sheared by mild sonication at 4°C. Nuclear extracts were prepared according to the protocol described by Dignam et al.14 The cytoplasmic fraction was the supernatant recovered after centrifugation of the crude cellular lysate to purify the nuclei. The protein concentrations of the extracts were measured by the Bradford method (Bio-Rad). A total of 30 pg of protein was mixed with an equal volume of 2X SDS gel loading buffer containing P-mercaptoethanol," was boiled, was fractionated by SDSIPAGE, and was electroblotted (Bio-Rad) onto a nitrocellulose membrane BA-S NC (Schleicher & Schuell, Keene, NH). Western blotting was performed using the enhanced chemiluminescence system according to the manufacturer's protocol (Amersham, Arlington Heights, IL). A total of 1 pg/mL of affinity-purified LAF-4 antibody in blocking buffer (PBS with 5% non-fat dry milk) was used for Western blotting.
Immunojhorescent cellular staining and confocal microscopy. The Nalm6 pre-B ce!l line and the K562 erythroleukemia cell line were grown in RPM1 supplemented with 10% fetal bovine serum. Cells were washed twice with PBS and diluted to 1 to 5 X IO4 cells/ mL in PBS. A total of 0.2 mL of the cell suspension was immobilized onto coverslips using a Cytospin 2 apparatus (Shandon, Astmoor, UK) at 450 rpm for 5 minutes at room temperature. Cells then were fixed with 2% paraformaldehyde for 20 minutes, washed, permeablized with 1% Triton-X 100 in PBS, and incubated with affinitypurified anti-LAF-4 antibody (1 pg/mL) in blocking solution (2% bovine serum albumin, 15% fetal bovine serum in PBS) for 2 hours at room temperature. After washing 4 times with PBS, cells were secondarily stained with fluorescein isothiocyanate-conjugated, donkey antirabbit Ig antibody (10 pg/mL; Jackson Immunoresearch Laboratories, West Grove, PA) and 0.8 mg/mL ethidium bromide in blocking solution for 20 minutes at room temperature. Cells were then washed sequentially with PBS and water, air-dried, and mounted onto slides using FluorSave (Calbiochem, San Diego, CA). Images of stained cells were acquired using a BioRad MRC 600 Confocal Laser Scanning Microscope. Images were processed using Adobe Photoshop software (Mountain View, CA) to produce 0-256 greyscale images.
Southern blot analysis. Genomic DNAs from human, mouse, chicken, and Drosophila were digested with restriction enzymes BamHI and EcoRI, and 10 pg of digested DNA was electrophoresed and transferred to a Hybond-N nylon membrane (Amersham). The Southern blot was hybridized according to the manufacturer's protocol with a 32P-labeled LAF-4 cDNA probe corresponding to amino acids 904-1227 derived from a pfu-PCR fragment from the clone E5 using primers 5'-CCGCGGATCCCACCATGGGCAACAGTT-TGTITACTTCA-3' and 5'-GCCGGGATCCTATGACAGGTG-GGCGCT-3'. The blot was then washed twice in 0.2X SSC Fig 2A) . The fragment encoding amino acids 1-295 was generated by pfu PCR with primers 5'-GGGCTCTAGAGACAGCTTCGACTTAGC-CCTGCTCCA-3' and 5'-TGGTITCTCCAGATCTACTCTCCT-3' using the E41 LAF-4 clone as a template. The fragment encoding amino acids 295-475 was also amplified by pfu PCR with primers ing the assembled full-length LAF-4 cDNA as a template. The fragment encoding amino acids 295-778 was directly excised by Bgl IV RomHI digestion of the assembled full-length LAF-4 cDNA. The CTACTCCAATGAAGTCCAT-3' and l7 primer (in vector). The fragment encoding amino acids 777-1227 was isolated as a BnmHI-CAT reporter construct used was G5EI K A T . containing five CAL4-Asp718 fragment from cDNA clone ES. The region of AF-4 that binding sites upstream of the adenovirus Elb TATA box.'" The was tested encoded amino acids 347-509 (Fig 2A; and was amplified vector pSV2Apap." expressing placental alkaline phosphatase. was by PCR from the AF-4 cDNA clone (FELN-IR) using /'fit polymerused as a control for transfection efficiency. A total of 4 X IO' HeLa we (Stratagene) with oligonucleotide S'-CCGCGGATCCCAGACcells were transfected for 6 hours using lipofectamine (10 &mL:
5"CCGCTCTAGAGGAGAGTAGATCTGGAGAAACCAA-3' US-
For GIBCO/BRL) with 1 pg of GAL4 expression vector, I pg of GzEl b-CAT, and 0. I pg of pSV2Apap. Cellular extracts were prepared 48 hours after transfection. CAT assays were performed as described'" except that the assay was performed at 37°C for 1 hour. The amount of extract used in the CAT assay was adjusted based on the placental alkaline phosphatase assay to normalize for transfection efficiency. The eluted LAF-4 was loaded onto a 0.2-mL double-stranded DNA cellulose column (Phamacia) equilibrated in Buffer B containing I O 0 mmol/L NaCI. The column was washed with 5 bed volumes of Buffer B containing 150 mmollL NaCl and was sequentially eluted with I bcd volume each of Buffer B containing 300 mmol/L, MO m m o K and I mol/L NaCl at 4°C. The purified radioactive-labeled protein from each fraction was measured by scintillation counting. Fractions were concentrated using a Centricon 30 filtration unit (Amicon) and were analy7d by SDS-PAGE. mia line.".'" In the present study. our particular aim was to identify nuclear factors that did not belong to previously known gene families. Therefore. we first identified the 52% of the sequences that were derived from novel genes. Those novel sequences that appeared to belong to known gene families, asjudged by the BLAST sequence homology algorithm.'" were excluded. We next identified sequences that had a high probability of being derived from the coding region of a gene by using the GRAIL algorithm." Finally, these novel openreading frames were screened for potential NLSs. We searched for NLSs resembling one of two motifs, the "bipartite" motif originally found in nucleoplasmin and a motif based on the NLS found in simian virus 40 large T antigen.:' These several criteria identified 23 cDNAs, and 12 of these were sub,jected to Northern blot analysis. Six cDNAs were potentially derived from lymphoid-restricted genes because they hybridized with mRNA from two lymphoid cell lines and not with mRNA from HeLa or K562 cell lines.
RESULTS

Cloning
Sequence analysis of long cDNA clones derived from one of these genes showed an intriguing homology with the AF-4 gene; therefore. we chose it for further study (Fig 2A) . The LAF-4 cDNA has an open-reading frame encoding I227 amino acids and a predicted protein of I34 kD, similar to the predicted size of AF-4 ( I3 1 kD: see Fig 2A) . The two proteins show homology throughout. although the similarity is greatest within an amino-terminal region (75% homology over 69 amino acids) and a carhoxy-terminal region (62% homology over 244 amino acids; see Fig 2B) . The central region of both proteins is rich in proline, serine. and glutamic acid residues. and within this region is a stretch of 260 amino acids over which LAF-4 and AF-4 are highly related (58% an anonymously sequenced cDNA encodes a protein with 78% similarity to LAF-4 over 45 amino acids (see Fig 2A;  EST00565) .
To explore the evolutionary conservation of the LAF-4 gene, a cDNA probe from the conserved carboxy-terminal region of LAF-4 was hybridized to a Southern "zoo" blot that included human, mouse. chicken, and Drosophila genomic DNAs (Fig 4) . LAF-4 hybridizing bands were readily detected in human. mouse. and chicken DNAs but not in Drosophila DNA, showing excellent evolutionary conservation of LAF-4 among vertebrates. The evolutionary conservation of LAF-4 was further addressed by isolating a partial mouse LAF-4 cDNA clone from a mouse pre-B-cell cDNA library. Sequencing of the S' 651 bp of this clone strongly suggested that it was derived from the amino terminus of mouse LAF-4 in that it encoded a protein bearing a striking 88% amino-acid identity to human LAF-4 over the region sequenced (Fig 2A) . Human and mouse LAF-4 are much more related to each other over this region than are human LAF-4 and human AF-4.
Expression of LAF-4 mRNA. A major 8.5-kb LAF-4 mRNA was detected by Northern blot analysis of human cell lines, consistent in size with the LAF-4 cDNA sequence presented above (Fig 3A) . Minor I .8-kb and 4.5-kb LAF-4 mRNA species were also detected and may be generated by alternative splicing. In support of this possibility, a 1.8-kb LAF-4 cDNA clone (E41; see Fig I ) obtained from the Raji cDNA library had a polyadenylation signal and encoded a predicted 38-kD LAF-4 protein comprised of amino-terminal amino acids 1-307 fused to additional 36 unidentified amino acids at its carboxy terminus (data not shown). This short-741 ened LAF-4 protein product has not been detected on Westem blots (see below). The 8.5-kb LAF-4 mRNA was detected in a pre-B-cell line (Nalm6) and a mature B-cell line (Ra.ji) but not in a nonlymphoid cell line, K562 (Fig 3A) . A more sensitive RNase protection assay for human LAF-4 mRNA confirmed that LAF-4 expression was undetectable in HeLa and K562 cells as well as in the T-cell line HUT78 and in the plasmacytoma line U266 (Fig K ) .
Mouse LAF-4 mRNA expression was similarly found to be cell-type-restricted. Northern blot analysis of mouse tissue mRNA showed that the mouse LAF-4 mRNA was smaller in size than human LAF-4 mRNA (6.1 kb 13 8.5 kb;
see Fig 3B) . This size difference most likely results from a shorter untranslated region in thc mouse LAF-4 mRNA, because the mouse and human LAF-4 proteins were of identical size on Western blots (see below). Mouse LAF-4 mRNA was at highest levels in thymus and spleen. was at lower levels in brain and lung, and was not detected in other tissues including heart, kidney, liver. and skeletal muscle.
A survey of a large number of human and mouse cell lines indicated that LAF-4 expression was developmentally regulated in the B-lymphoid lineage ( Table 1 ) The 135-kD LAF-4 protein was detectable by Western blot in nuclear extracts of pre-B-and B-cell lines (Fig S. lanes 6, 9. and 10) but not in the cytoplasmic fraction (Fig  5 , lane 7) , indicating that LAF-4 was a nuclear protein.
The nuclear localization of LAF-4 was confirmed by confocal
For personal use only. on July 14, 2017. by guest www.bloodjournal.org From immunofluorescence microscopy using the affinity-purified anti-LAF-4 antibodies (Fig 6) . Immunofluorescent staining was detected in the nucleus of Nalm6 pre-B cells that express LAF-4 but not in K562 cells that do not express LAF-4. This cell-type-specific staining suggests that the immunofluorescence signal is directed towards the the 135-kD LAF-4 protein and not towards the 70-kD protein detected in all cell types by Western blot analysis. The LAF-4 nuclear immunofluorescence showed an unusual granular pattern, sparing the nucleoli, a pattern that was distinct from the diffuse nuclear staining observed with many sequence-specific, DNA-binding transcription factors.
LA F-4 and AF-4 have transcriptional transactivation potpntial. To begin to dissect the functional domains of LAF-4 and AF-4, we tested whether regions of these proteins could activate transcription when fused to the GAL4 DNAbinding domain (Fig 7A) . Expression vectors for GAIA/ LAF-4 and GAL4IAF-4 fusion proteins were transfected into HeLa cells together with a CAT reporter construct in which five copies of the GAL4 DNA-binding motif were cloned upstream of a minimal Elb promoter. An expression vector for the GAL4-Ela fusion protein was also used as a positive control (Fig 7A, lane l ) , and an expression vector for the GAL4 DNA-binding domain alone was used as a negative control (Fig 7A. lane 7) .
Both LAF-4 and AF-4 had potent transcriptional activation domains in this assay system. LAF-4 had two separable transcriptional activation domains, one at the amino terminus see Fig 7A, lane 3 ) and one in a central region of the protein rich in proline, serine, and acidic residues terminus of LAF-4 was inactive in this assay. A region of AF-4 corresponding to the central LAF-4 transactivation domain also activated transcription strongly (AF-4'47~""; see Fig 7A, lane 2) . The transcriptional transactivation domains are shown schematically in Fig 7B. Interestingly, the transactivation domain of AF-4 is retained in the MLLiAF-4 fusion protein in t(4; 1 I ) ALL and, thus, may contribute to the oncogenic potential of this fusion oncoprotein. U F -4 protein can interact with DNA. The potential of LAF-4 to bind to DNA was assessed by double-stranded DNA cellulose chromatography. To purify the full-length LAF-4 protein, the LAF-4 cDNA was modified so as to add a FLAG epitope tag at the amino terminus of the protein. This modified LAF-4 protein was translated in vitro in the presence of "S-methionine and purified by anti-FLAG immunoaffinity chromatography. The purified protein consisted of a 1 3S-kD, presumably full-length, LAF-4 protein and several lower molecular weight species (Fig 8, lane 3) . Because they were selectively purified on the anti-FLAG affinity resin, these smaller proteins most likely represent incomplete translation products derived from the LAF-4 mRNA. After binding to double-stranded DNA cellulose, the full-length, 135-kD LAF-4 protein was eluted in the 600 mmol/L fraction, whereas the smaller protein species were eluted in the 300 mmol/L fraction (Fig 8) . In control experiments, the POU domain transcription factor, Oct-3, bound to DNA cellulose and eluted in the 300 mmol/L fraction (data not shown). As a negative control, the luciferase protein did not bind (data not shown). Thus, in vitro-translated, full-length LAF-4 binds strongly to double-stranded DNA cellulose either directly or potentially together with a factor(s) derived from the reticulocyte lysate. nuclear factor with homology to AF-4, the gene fused to MLL in t(4; 1 I ) ALL. Because it showed no strong homology with previously cloned proteins, prior sequence analysis of AF-4 had been unrevealing. Thus, the cloning of LAF-4 allowed us to define the LAF-4/AF-4 gene family as a novel family of nuclear factors. The LAF-4/AF-4 family most likely includes additional human genes because we have found an anonymously sequenced cDNA that encodes a protein with strong sequence similarity to LAF-4 and AF-4. Because we readily detected genes cross-hybridizing with human LAF-4 in both mouse and chicken genomic DNA, the LAF-4/AF-4 family is strongly conserved in evolution. Similarly, we have detected potential homologues of human AF-4 in both mouse and chicken (data not shown). The evolutionary conservation of LAF-4 was further confirmed by the strong sequence similarity between human and mouse LAF-4 cDNAs. Such impressive conservation of the LAF-4/AF-4 gene family within vertebrates points to an important functional role for protein products of these genes.
LAF-4 expression was found to be highest in lymphoid cells (Fig 3 and Table I ), whereas AF-4 expression is more widespread." Within the B-cell lineage, LAF-4 expression was highest in pre-B cells, intermediate in mature B cells, and low or absent in plasmacytomas. High levels of LAF-4 were found in thymus, with low or undetectable levels in mature T-cell lines. These observations suggest that LAF-4 is expressed at highest levels in lymphoid precursor cells and, thus, may regulate the early steps in lymphocyte differentiation. Furthermore, it is conceivable that the downmodulation of LAF-4 in plasmacytomas reflects a regulatory switch that is required for terminal differentiation in the Blymphoid lineage. AS with other lymphoid-restricted transcription factors such as Oct-2" and BSAPPaxS," LAF-4 is also expressed outside of the lymphoid compartment in a limited number of tissues. This most likely reflects an economy of transcription factor utilization in cellular differentiation.
The potential function of LAF-4 as a transcription factor is supported by its nuclear localization and the finding that it possesses two potent transcriptional activation domains. At least one of these transcriptional activation domains is functionally conserved in AF-4. In addition, LAF-4 was able to bind nonspecifically to double-stranded DNA cellulose, although this biochemical property is not unique to transcription factors but is also a feature of nuclear proteins with disparate functions. Indeed, by using the purified LAF-4 protein to select binding sites from a pool of random oligonucleotides, we could not define a sequence motif to which LAF-4 binds preferentially (data not shown), although we can not rule out this possibility. The notion that LAF-4 may not be a canonical sequence-specific DNA-binding transcription factor is supported by its unusual granular immunofluorescence visualized by confocal microscopy. By contrast, most sequence-specific DNA-binding transcription factors For personal use only. on July 14, 2017. by guest www.bloodjournal.org From show a diffuse and homogeneous nuclear immunofluorescence with sparing of the nucleoli. Conceivably, LAF-4 may function at discrete sites within the nucleus, or act on only a subset of chromosomal loci. The potential for LAF-4 to associate with other proteins may well help to decipher the exact role of LAF-4 in transcriptional regulation.
Finally, our data have implications for the molecular pathogenesis of t(4; 1 l ) ALL. The MLL/AF-4 fusion protein generated by this translocation lacks a carboxy-terminal transcriptional activation domain found in wild-type MLL.26 The AF-4 transcriptional activation domain that we have defined is retained in the MLWAF-4 fusion protein and, thus, may functionally replace the normal MLL activation domain. However, different transcriptional activation domains are distinguishable from each other in several ways. First, the strength of activation domains can vary widely and, in some cases, may show cell-type specificity. Furthermore, activation domains can contact distinct components of the general transcriptional machinery.*' Thus, it is certainly conceivable that the replacement of the MLL activation domain with the AF-4 activation domain could result in aberrant regulation of certain key target genes. However, it is also possible that other domains of AF-4 besides its transactivation domain contribute to the oncogenic action of MLL/AF4. In particular, the extreme carboxy terminus of AF-4 is highly conserved with LAF-4 and a protein encoded by an anonymous cDNA and, thus, may represent an important, but as yet obscure, functional domain that contributes to transformation by MLL/AF-4. Therefore, a functional dissection of these domains in the context of the MLL/AF-4 fusion protein is an important goal.
Another MLL fusion partner, ENL, has recently been shown to be a nuclear protein and to contain an activation domain that is retained in the MLWENL fusion protein.9 This ENL activation domain could not activate transcription from a minimal promoter containing only a TATA box but could activate transcription when bound upstream of the thymidine kinase promoter. In the present study, the AF-4 activation domain was able to activate a minimal promoter, suggesting that it is either stronger than the ENL activation domain or functions in a mechanistically distinct fashion. ENL is highly related in two regions to another MLL translocation partner, the AF-9 gene, which is translocated in t(9; 11) AML.' Both ENL and AF-9 are related in sequence to a yeast transcription factor, ANC1'; thus, it is likely that AF-9 is also a nuclear factor. The AF-X1 gene,2x which is fused to MLL in t(X; 11) leukemias, shows sequence homology to the forkheadwinged helix transcription factor family (our unpublished observations). The other MLL translocation partners have not been shown to be nuclear proteins, but several have potential nuclear localization signals. Two of these proteins, AF-17*' and AF-1 0,30 are novel zinc finger, leucine zipper proteins that are homologous to each other.
Therefore, when considered together, the MLL fusion partners are clearly not randomly chosen from the genome. Rather, in several reports, including the present study, the MLL fusion partners have defined novel families of nuclear transcription factors. The MLL translocations consistently fuse MLL in frame with the translocation partners. Furthermore, the lineage of the acute leukemia that is caused by an MLL translocation is correlated strongly with the fusion partner: MLL/AF-4 fusions are found, in large measure, in ALL, whereas MLL/AF-9 fusions are found exclusively in AML.' Recently, two AML cases and a gastric carcinoma cell line have been shown to have internal duplications of the MLL gene, without any fusion of MLL to another gene."-" In the gastric carcinoma cell line, no normal MLL transcript could be found, suggesting the possiblity that loss of normal MLL function may contribute to the molecular pathogenesis of certain tumors."
On the other hand, the present demonstration that a strong transcriptional activation domain from AF-4 is fused to MLL in t(4; 11) ALL would support the notion that this leukemia is caused, in part, by a dominant gain of function. Thus, whereas MLL is clearly central to a molecular understanding of these leukemias, it will be important to further delineate the contributions made by the MLL translocation partners, such as AF-4, to the molecular derangements that lead to malignant transformation.
